New Findings in Drug-Induced Receptor Activity Using Roche´s xCELLigence System
PENZBERG, Germany, February 15, 2012 /PRNewswire/ –
A research team led by Dr. Michel Bouvier at the Institute for Research in Immunology
and Cancer (IRIC) of the University of Montreal in Quebec, used the Roche xCELLigence SP
[https://www.roche-applied-science.com/sis/xcelligence/index.jsp?&id=xcect_030100 ] to
measure changes in cell response following ligand stimulation (Stallaert et al., 2012,
PloS ONE 7(1): e29420). According to their findings, selective pharmacological inhibition
of specific arms of the beta2AR signaling network was able to correlate the differential
contribution of signaling events to specific components of the cell response. The
essential role of intracellular Ca2+ in the cell response also led to the discovery of a
novel beta2AR-promoted Ca2+ mobilization event.
The discovery that drugs targeting a single G protein-coupled receptor (GPCR) can
differentially modulate distinct subsets of the receptor signaling repertoire is a very
important step in drug discovery. Findings of the present study underscore the power of
using real-time cell monitoring to dissect the pluridimensionality of GPCR signaling using
integrative approaches for a comprehensive readout of drug-induced cellular activity.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare
with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest
biotech company with truly differentiated medicines in oncology, virology, inflammation,
metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based
cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare
strategy aims at providing medicines and diagnostic tools that enable tangible
improvements in the health, quality of life and survival of patients. In 2011, Roche had
over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group
posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned
member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For
more information: http://www.roche.com.
An ultra-modern research hub and training centre located in the heart of the
University of Montreal, the Institute for Research in Immunology and Cancer (IRIC) was
created in 2003 to shed light on the mechanisms of cancer and discover new, more effective
therapies to counter this plague. IRIC’s 29 research teams operate according to a model
that is unique in Canada. Its innovative approach to research has already led to
discoveries that will, over the coming years, have a significant impact on the fight
For life science research only. Not for use in diagnostic procedures.
XCELLIGENCE And E-PLATE are trademarks of Roche.
All other product names and trademarks are the property of their respective owners.
For further information please contact: Roche Diagnostics Dr. Burkhard Ziebolz Phone: +49-8856-604830 Email: firstname.lastname@example.org
SOURCE Roche Diagnostics GmbH